We present 3 cases of autoimmune liver disease in human immunodeficiency virus (HIV)-infected patients and describe the different diagnostic and therapeutic approaches used in each case. The first patient was diagnosed with primary biliary cholangitis (PBC) with features of autoimmune hepatitis (AIH), requiring second-line therapy due to incomplete response to ursodeoxycholic acid. The second patient was diagnosed with AIH with features of PBC and had the particular challenges of presenting with advanced liver fibrosis and having a past history of disseminated cytomegalovirus infection. The last case concerns an AIH with acute liver injury, successfully treated with corticosteroids and azathioprine. Recently, the number of patients on antiretroviral therapy (ART) for HIV disease has increased significantly. Therefore, more patients with this chronic infection have been diagnosed with autoimmune diseases, leading to concerns regarding immunosuppressive therapies in this population. With these cases, we alert for these increasingly incident diseases and support the safety of immunosuppressive therapies, provided that HIV is suppressed with ART.

© 2022 The Author(s). Published by S. Karger AG, Basel

Hepatite autoimmune · Colangite biliar primária · VIH · Síndrome de reconstituição imune ·

Apresentamos três casos distintos de doença hepática autoimune em doentes com infeção pelo vírus da imunodeficiência humana (VIH), descrevendo as diferentes abordagens diagnósticas e terapêuticas. O primeiro doente foi diagnosticado com colangite biliar primária (CBP) com caraterísticas de hepatite autoimune (HAI), necessitando de terapêutica de segunda linha por resposta incompleta ao ácido ursodesoxicólico (AUDC). O segundo doente foi diagnosticado com HAI com caraterísticas de CBP, com as particularidades de se apresentar com fibrose hepática avançada e de ter tido uma infeção disseminada pelo citomegalovírus. O terceiro caso apresentou-se como uma hepatite aguda grave, tratada com corticoterapia e azatioprina. Recentemente, o número de doentes sob terapêutica antirretroviral (TARV) para a infeção pelo VIH tem aumentado significativamente. Consequentemente, mais doentes com esta infeção crónica têm sido diagnosticados com doenças autoimunes, levando a receios na administração de terapêuticas imunossupressoras. Com esta série de casos pretendemos alertar para esta incidência crescente e para a segurança dos imunossupressores, desde que os doentes apresentem a sua infeção pelo VIH controlada com a TARV.

Introduction

In recent years, the number of patients on antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection has increased significantly [1]. Although antiretroviral drug-induced liver injury is the first hypothesis when elevation of liver enzymes occurs after starting these therapies, immune reconstitution-related autoimmune hepatitis (AIH) must be considered. In HIV-infected patients, HIV-associated cholangiopathy, co-infection with hepatitis B or C virus, opportunistic infections, alcohol abuse, and nonalcoholic fatty liver must also be excluded, among others.

About three dozen cases of AIH have been described in HIV-positive patients with no prior history of abnormal liver enzymes, who developed transaminase abnormalities months to years after starting ART [2-5]. These cases are mainly of AIH, with only two overlap syndromes with primary biliary cholangitis (PBC) and AIH being reported in the literature [6, 7]. The mechanism for this increasingly described entity of immune reconstitution syndrome is not fully understood, but probably involves the rapid increase in CD4+ lymphocyte number after starting ART. In AIH, cellular infiltrates in the liver are rich in CD4+. In particular, the pro-inflammatory Th17 subtype that releases IL-17 has been found to be elevated in AIH. Furthermore, these patients have decreased numbers of Treg cells, which suppress effector T cells and maintain tolerance to self-antigens. The rapid increase in CD4+ cells following ART may produce a larger proportion of Th17 cells without appropriate Treg cell numerical and functional reconstitution, thereby creating a “perfect storm” for AIH onset [2]. Additionally, other autoimmune disorders, such as vasculitis, systemic lupus erythematosus, psoriasis, and Graves’ disease, have been described in HIV patients treated with ART [3].

It is challenging to start immunosuppressive therapy in patients with HIV infection, given the risk of worsening HIV status and increasing the risk of opportunistic infections or malignancies [5]. However, cases of AIH in HIV-infected patients have been described and successfully managed with either prednisolone alone or in combination with azathioprine, while on ART [3-5]. From the published data, only 4 cases of life-threatening infections occurred in HIV patients with AIH treated with immunosuppressors [8], although some reports have insufficient follow-ups. Current AIH guidelines recommend individualized immunosuppressive therapy in this population [9]. Particular attention is also needed for possible drug-drug interaction between immunosuppressive medications like azathioprine and antiretroviral medications, as they share common elimination and metabolism pathways such as cytochrome P450 enzyme system or P-glycoprotein and multidrug resistance-associated protein pathways [5].

Case ReportCase 1

This case concerns a 59-year-old Caucasian man with HIV (CDC Atlanta stage A1 [10]) infection controlled with abacavir, dolutegravir, and lamivudine (ABC/DTG/3TC) and hypercholesterolemia treated with simvastatin. He was otherwise healthy and fit, his body mass index (BMI) being 22.6 kg/m2. Previously to ART, he already had pruritus and a slight elevation of liver enzymes, with an alkaline phosphatase (ALP) of 154 U/L, gamma-glutamyltransferase (GGT) of 201 U/L, and alanine transaminase (ALT) of 68 U/L. A significant increase in hepatic enzymes occurred 3 years after starting antiretrovirals: ALP 541 U/L (4 times the upper limit of normal [ULN]), GGT 1,025 U/L (17 times the ULN), and ALT 262 U/L (6 times the ULN), with normal bilirubin. The patient denied excessive alcohol consumption and intake of new drugs or herbal and dietary supplements (HDS). Viral and metabolic liver diseases were excluded. Positive antinuclear antibodies (ANA) (1:640), positive anti-mitochondrial antibodies (AMA) (1:160), elevated immunoglobulin G (1,824 mg/dL), and immunoglobulin M (478 mg/dL) were found. Abdominal ultrasound and computed tomography revealed a normal sized liver without bile duct alterations. Magnetic resonance cholangiopancreatography was not performed due to orthopedic metallic material. Liver biopsy revealed a mixed inflammatory infiltrate with lymphocytes, plasmocytes, neutrophils, and some eosinophils, with features of cholangitis, such as exuberant ductular proliferation and intraepithelial lymphocytes in bile ducts, without cholestasis or steatosis, with moderate interface hepatitis with bridging necrosis and a chronicity index of 2/6 according to Ishak criteria (shown in Fig. 1).

Fig. 1.

Liver biopsy (9 portal spaces) revealed an intense inflammatory infiltrate with features of cholangitis (exuberant ductular proliferation (arrows exampling some) and intraepithelial lymphocytes in bile ducts) without cholestasis, with moderate interface hepatitis and bridging necrosis. Hematoxylin and eosin, ×20.

A diagnosis of PBC with features of AIH, meeting Paris criteria for AIH-PBC overlap syndrome (ALP >2 times the ULN and GGT >5 times the ULN, positive AMA >1:40 and florid bile duct lesion on histology for PBC; ALT more than 5 times the ULN and histology with moderate interface hepatitis for AIH), was established, and ursodeoxycholic acid (UDCA) was started at 1,000 mg/day. According to Paris II criteria (ALP more than 1.5 times the ULN or aspartate transaminase [AST] more than 1.5 times the ULN or bilirubin more than 1 mg/dL), the patient had an incomplete response to UDCA at 12 months (ALP 541–261 U/L), despite ALT and AST improvement (from 150 U/L and 103 U/L to 51 U/L and 46 U/L, respectively). Although most recent guidelines suggest the association with obeticholic acid in these cases [11], data concerning its use with concomitant ART were lacking. Because the association of UDCA with bezafibrate has been shown to be promising as an alternative [12], bezafibrate 400 mg/day was added after confirming its safety in combination with ART. At this point, ALT and AST were at the ULN. A substantial improvement 6 months after starting bezafibrate was noted, with ALP normalization (91 U/L) and a significant reduction in GGT (318–140 U/L). One year after concomitant therapy with UDCA and bezafibrate, ALT, AST, and ALP are within the normal range, with a slight GGT elevation (110 U/L). Transient elastography improved from 13.3 kPa to 9.1 kPa. Although this patient met Paris criteria for “PBC with secondary AIH,” a normalization of ALT and immunoglobulin G was achieved with the treatment for PBC. Therefore, no immunosuppressive treatment was initiated.

Case 2

This case concerns a 49-year-old Caucasian man with HIV infection diagnosed in the context of disseminated cytomegalovirus disease (esophagitis and proctitis) (CDC Atlanta stage C3 [10]), with complete remission and with recovery of immunological state (CD4 count> 500 cels/μL) and suppression of viral load with ABC/3TC/DTG since then. He was otherwise fit and had a BMI of 24.3 kg/m2. An oscillating elevation of hepatic enzymes was noticed 2 years later, with maximum values of ALP 289 U/L, GGT 554 U/L, ALT 613 U/L, and AST 371 U/L, with normal bilirubin. He denied excessive alcohol intake, recently introduced drugs, or HDS. An extensive liver panel excluded viral and metabolic liver diseases. The patient had positive ANA (1:640), positive AMA (1:80), and elevated immunoglobulin G (2,536 mg/dL). Abdominal computed tomography revealed a cirrhotic liver. Liver biopsy, performed 6 months after starting UDCA 13 mg/kg/day (which had been initiated in the Infectious Diseases Clinic, previously to hepatology referral), confirmed fibrosis 5/6 according to Ishak criteria and features compatible with AIH (lymphoplasmacytic infiltrate, moderate to severe interface hepatitis, and emperipolesis) and biliary inflammation without duct destruction (shown in Fig. 2). Upper endoscopy excluded esophageal varices.

Fig. 2.

Liver biopsy (6 portal spaces) revealing features of autoimmune hepatitis (moderate to severe lymphoplasmacytic infiltrate, interface hepatitis, and emperipolesis) with ductular proliferation without ductopenia. Arrows showing inflammatory cells permeating through hepatocytes. Hematoxylin and eosin, ×20.

A diagnosis of AIH with features of PBC (meeting Paris criteria for overlap syndrome: ALP >2 times the ULN, GGT >5 times the ULN, and positive AMA >1:40 for PBC; histology with moderate to severe interface hepatitis and ALT >5 times the ULN for AIH) was established. Considering the severity of his initial HIV presentation and concerns regarding immunosuppression in this scenario, a decision was made to start prednisolone monotherapy, at an initial dose of 60 mg/day, without azathioprine. A significant analytical improvement was noted 1 month later (AST 244–42 U/L, ALT 326–69 U/L, ALP 170–104 U/L, GGT 276–45 U/L). Since interferon gamma release assay was positive, the patient was treated with isoniazide for latent tuberculosis for 9 months, while tapering prednisolone. However, the dose required to maintain a complete biochemical response was 15–17.5 mg. Recently, almost 2 years after diagnosis and after completing SARS-CoV-2 vaccination, azathioprine was added at 50 mg/day (0.5 mg/kg) which allowed for prednisolone tapering to 10 mg, with sustained complete biochemical response.

Case 3

This case concerns a 53-year-old black overweight woman (BMI 28.4 kg/m2) with long-term HIV infection (CDC Atlanta A2 stage [10]) treated with darunavir, emtricitabine, tenofovir, and ritonavir, with a good immunological state. She presented with acute abdominal pain, nausea, and new-onset jaundice, without fever or encephalopathy. Liver enzymes were increased (ALT 158 U/L, AST 395 U/L, ALP 171 U/L, GGT 328 U/L, and total bilirubin 9.76 mg/dL), and prothrombin time prolonged (20.9 s, with INR 1.8), hence meeting criteria of acute liver injury. She denied alcohol consumption, recently introduced drugs, or HDS. Abdominal Doppler ultrasound was normal. Viral hepatitis was excluded. Due to positive ANA (1:640) and significantly increased immunoglobulin G (5,100 mg/dL), liver biopsy was performed. Histology revealed features typical of AIH (lymphoplasmacytic infiltrate, interface hepatitis, emperipolesis, and hepatocellular rosette formation) with severe inflammatory activity, massive bridging necrosis, and parenchymal collapse, with an activity index of 13/18 and a chronicity index of 3/6 according to Ishak criteria (shown in Fig. 3).

Fig. 3.

Liver biopsy (10 portal spaces) revealing features of autoimmune hepatitis (lymphoplasmacytic infiltrate, with severe intralobular inflammatory activity (stars evidencing inflammatory infiltrate and crosses evidencing plasma cells aggregates) and necrosis (arrows showing apoptotic bodies). Hematoxylin and eosin, ×20.

Prednisolone was started (initial dose 50 mg/day), and the patient was safely discharged after 2 weeks. Azathioprine was added 1 week after discharge, when MELD-Na improved from 23 to 15 and with a total bilirubin of 4.75 mg/dL at this time, while tapering corticosteroids. The patient reached complete biochemical response almost 1 year after the initial presentation, while on 10 mg/day prednisolone and 50 mg azathioprine. Although liver biopsy during acute presentation showed a chronicity index of 3/6, more recent transient elastography values range from 20.2 to 15.1 kPa (1 month and 1 year after biochemical remission, respectively) and she presents fluctuating mild thrombocytopenia (with no varices on upper endoscopy), suggesting the development of compensated advanced chronic liver disease [13]. At the time of publication (2 years after the initial presentation), the patient remains in biochemical remission with 7.5 mg/day of prednisolone and 50 mg/day of azathioprine.

Conclusion

Our three reports (Table 1) are different manifestations from a same spectrum of autoimmune liver diseases, all arising in patients with HIV infection. The first case has the particularity of bezafibrate success after UDCA incomplete response in a patient with PBC with features of AIH, with the concern of unknown drug interactions between ART and the currently recommended second-line drug, obeticholic acid. The second case has additional immunosuppression concerns, since HIV diagnosis was made during a disseminated cytomegalovirus workup and due to the advanced liver disease. Moreover, the use of isoniazid for latent tuberculosis adds further complexity to AIH management, since multiple potential causes for elevated liver enzymes can be present (AIH, azathioprine, or isoniazid-induced hepatotoxicity). The third case, which had a severe acute presentation with acute liver injury, occurred after our experience with the first 2 cases. This not only led to a more straightforward diagnosis, but also allowed for greater confidence when starting immunosuppression. The authors point out that the second patient maintained CD4+ lymphocyte counts >200 cells/μL and the first and third patient >400 cells/μL, with negative HIV viral load during immunosuppressive treatment, and no prophylactic treatment for opportunist infections was needed. No adverse events related to either UDCA, bezafibrate, prednisolone, or azathioprine were reported during follow-up, including infectious complications – Table 1.

Table 1.

Comparison between the three cases of autoimmune liver disease in HIV-infected patients

With this case series, we also emphasize the importance of liver biopsy, given the extensive differential diagnosis in patients with liver function test abnormalities and an HIV infection, as previously mentioned. To conclude, in an era of generalization of ART therapy, it is important to remain alert to these increasingly incident autoimmune entities and their diagnostic and therapeutic challenges.

Acknowledgements

The designated corresponding author of the above article submitted for consideration of publication to Portuguese Journal of Gastroenterology confirms that (i) all named authors agree to the submission of the paper to Portuguese Journal of Gastroenterology; (ii) all authors who contributed to the design and writing of the paper have been named on the paper; (iii) the paper is not currently under review by another journal; and (iv) the paper has not been accepted for publication elsewhere.

Statement of Ethics

This study was reviewed and approved by the Ethics Committee of Hospital Prof. Doutor Fernando Fonseca on March 16, 2022. Written informed consent was obtained from all participants for publication of the details of their medical case and any accompanying images.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No fundings were received.

Author Contributions

Maria Ana Rafael: manuscript writer and literature review. Filipa Bordalo Ferreira: patients’ physician and literature review. Rita Theias Manso: histological diagnosis. Francesca Peruzzu: patients’ physician and manuscript supervisor. Mariana Cardoso: patients’ physician and manuscript supervisor.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.